Journal
TRENDS IN MOLECULAR MEDICINE
Volume 16, Issue 6, Pages 268-276Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.molmed.2010.04.007
Keywords
-
Funding
- National Institutes of Health [NS11766, HD32062]
- Muscular Dystrophy Association
- Ellison Medical Foundation
- Alzheimer Drug Discovery Foundation
- Marriott Mitochondrial Disorder Clinical Research Fund (MMDCRF)
- EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD032062] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS011766, P01NS011766] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Until even only a few years ago, the idea that effective therapies for human mitochondrial disorders resulting from the dysfunction of the respiratory chain/oxidative phosphorylation system (OxPhos) could be developed was unimaginable. The obstacles to treating diseases caused by mutations in either mitochondria! DNA (mtDNA) or nuclear DNA (nDNA), and which had the potential to affect nearly every organ system, seemed overwhelming. However, although clinically applicable therapies remain largely in the future, the landscape has changed dramatically and we can now envision the possibility of treating some of these disorders. Among these are techniques to upregulate mitochondrial biogenesis, enhance organellar fusion and fission, shift heteroplasmy and eliminate the burden of mutant mtDNAs via cytoplasmic transfer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available